Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Conditions: Non-muscle Invasive Bladder Cancer; HER-2 Protein Overexpression Interventions: Drug: Disitamab vedotin; Drug: Bacillus Calmette Guerin Vaccine Sponsors: Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bladder Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | HER2 | Research | Vaccines